<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226757</url>
  </required_header>
  <id_info>
    <org_study_id>HER2-targeting in EGFR-mutated</org_study_id>
    <nct_id>NCT02226757</nct_id>
  </id_info>
  <brief_title>Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients</brief_title>
  <official_title>Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on
      standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2
      expression, patients can participate in the trial after obtaining informed consent.

      Patients will be treated with weekly paclitaxel-trastuzumab.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>NSCLC</condition>
  <condition>HER2-expression</condition>
  <condition>EGFR-mutation</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel-trastuzumab weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel-trastzumab</intervention_name>
    <description>Trastuzumab
Dose:
First dose: 4 mg/kg IV
Subsequent doses: 2 mg/kg every week IV.
The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.
Paclitaxel
- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab</description>
    <arm_group_label>Paclitaxel-trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage IV non-squamous NSCLC patients.

          -  Patients must have been detected with an activating EGFR mutation at baseline and must
             have yet progressed on erlotinib, gefitinib or afatinib monotherapy in daily dose of
             150 mg, 250 mg or 40 mg respectively. (Patients with unknown mutation status that have
             exhibited a response to these agents or stable disease for at least 6 months while on
             treatment with gefitinib or erlotinib are also eligible).

          -  Rebiopsy after having acquired resistance to TKI-treatment must have been performed
             and HER2-overexpression (positive immunohistochemistry staining) must have been
             detected.

          -  There must be at least one measurable disease site, according to RECIST 1.1 criteria.

          -  WHO performance status 0-2.

          -  Willing and able to comply with the study prescriptions.

          -  18 years or older.

          -  Not pregnant or breast feeding and willing to take adequate contraceptive measures
             during the study.

          -  Ability to give written informed consent before patient registration.

        Exclusion Criteria:

          -  No uncontrolled infectious disease.

          -  No other active malignancy.

          -  No major surgery (excluding diagnostic procedures like e.g. mediastinoscopy or VATS
             biopsy) in the previous 4 weeks.

          -  No treatment with investigational drugs.

          -  No known hypersensitivity to trastuzumab-paclitaxel

          -  No symptomatic brain metastases.

          -  History of coronary artery disease, NYHA class III or IV and Left Ventricular Ejection
             Fraction (LVEF) of &lt;45%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justine Kuiper, MD</last_name>
    <phone>0031204442214</phone>
    <email>jl.kuiper@vumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>VU University medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justine Kuiper, MD</last_name>
      <phone>+31204442214</phone>
      <email>jl.kuiper@vumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>August 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>August 25, 2014</last_update_submitted>
  <last_update_submitted_qc>August 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. dr. E.F. Smit</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>HER2-expression</keyword>
  <keyword>EGFR-mutation</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Paclitaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

